Form 8-K NeuBase Therapeutics, For: Oct 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Citi cuts investment banking analyst program to two years - Bloomberg
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
RBC Capital Downgrades NeuBase Therapeutics (NBSE) to Sector Perform
October 18, 2022 5:23 AM EDTRBC Capital analyst Brian Abrahams downgraded NeuBase Therapeutics (NASDAQ: NBSE) from Outperform to Sector Perform with a price target of $1.00 (from $12.00).
The analyst comments "On Friday, NBSE announced a major restructuring as part of a cost-saving measure and we... More



